Algernon Pharmaceuticals Inc. 839 likes. Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) CEO Christopher Moreau tells Proactive he will be one of three emerging companies that will present at Proactive’s One2One virtual investor conference on Tuesday, December 8, at 1:30PM. Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation. Algernon Pharmaceuticals is a drug repurposing company. Christopher J. Moreau CEO CONTACT INFORMATION. Learn more about Full Interview: Algernon Pharmaceuticals Updates Phase 2 Human Testing … Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation. Hosted by Proactive's Christine Corrado, the event kicks off on Tuesday at 1.30 PM ET. Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Find real-time AGNPF - Algernon Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. CONTACT INFORMATION. Christopher Moreau, CEO of UF startup Algernon Pharmaceuticals, a clinical-stage pharmaceutical development company, joins Steve Darling from Proactive Vancouver to provide an update about its initiated phase 2 clinical study of NP-120 for COVID-19 on infected patients in South Korea. Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, focuses in the areas of nonÂ-alcoholic steatohepatitis, liver disease, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury. CONTACT INFORMATION. Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation. … Halt Time (ET): 2:03 PM IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil VANCOUVER, British Columbia, Aug. 05, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.… Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Funds controlled by AlphaNorth Asset Management hold shares of the following companies discussed in the broadcast: Algernon Pharmaceuticals 6. About Algernon Pharmaceuticals Inc. Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF). Christopher J. Moreau CEO Algernon Pharmaceuticals Inc. 604.398.4175 ext 701 Moreover, Algernon is about to begin a phase … .the company recently announced the first patient has been enrolled in its multinational human Phase 2b/3 COVID trial of Ifenprodil. "Algernon Pharmaceuticals Inc. is betting that this quiet and unassuming safe generic drug, Ifenprodil, may soon become a global blockbuster. Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to bring news the company has enrolled their final patient multinational Phase 2b/3 human study of Ifenprodil for the treatment of COVID-19. VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the final patient has been enrolled in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of … Christopher J. Moreau CEO Algernon Pharmaceuticals Inc. 604.398.4175 ext 701 info@algernonpharmaceuticals.com investors@algernonpharmaceuticals.com www.algernonpharmaceuticals.com About Algernon Pharmaceuticals Inc. Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and … Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB: AGNPF) is one of three emerging companies that will present at Proactive’s virtual investor conference on Tuesday, December 8. CONTACT INFORMATION. … Algernon Pharmaceuticals Announces Green Light From Data and Safety Monitoring Board to Continue its Multinational 2b/3 Human Study of Ifenprodil for Treatment of … CONTACT INFORMATION. Stock analysis for Algernon Pharmaceuticals Inc (AGNPF:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile. View recent trades and share price information for Algernon Pharmaceuticals Inc and other shares. VANCOUVER, British Columbia, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 154 patients in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation. Disclosures for Dr. Mark Swaim: I, or members of my immediate household or family, own securities of the following companies discussed in the broadcast: Algernon Pharmaceuticals The latest Algernon Pharmaceuticals Inc share price. Algernon Pharmaceuticals, Inc. engages in the innovation of specialized mass spectrometry. Christopher J. Moreau CEO Algernon Pharmaceuticals Inc. 604.398.4175 ext 701. info@algernonpharmaceuticals.com Company: Algernon Pharmaceuticals Inc. CSE Symbol: AGN. VANCOUVER, BC, Dec. 14, 2020 /CNW/ - The following issues have been halted by IIROC:. Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW | OTCQB: AGNPF) is a clinical stage pharmaceutical development company. Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough. It involves in the development of commercially viable methods such as of breath analysis screening technologies for the early screening of diseases such as lung, breast cancers, neurodegenerative diseases, tuberculosis, diabetes, liver diseases, and others. CEO Chris Moreau provides an update and recap with Cyndi Edwards of PR Media Now on Facebook Live - October 28, 2020.